44 states accuse big pharma of price fixing generics market
13-05-2019
Teva settles Sensipar patent dispute with Amgen
04-01-2019
FTC agrees to re-open Actavis and Watson merger decision
19-12-2018
parbradyphoto / iStockphoto.com
Teva Pharmaceutical and the US Federal Trade Commission (FTC) have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Teva Pharmaceutical, Federal Trade Commission, generic drugs, reverse-payment, antitrust
